Nursing Responsibilities for Buscopan (Hyoscine Butylbromide) Administration

Buscopan® (hyoscine butylbromide) is an antispasmodic used for abdominal cramps, IBS, biliary/renal colic, and bladder spasms. It acts peripherally (quaternary amine—does not cross BBB), minimizing CNS effects.

Pre-Administration Assessment

  • Allergies: Hyoscine, other anticholinergics.
  • Contraindications: Glaucoma (narrow-angle), myasthenia gravis, paralytic ileus, pyloric stenosis, obstructive uropathy, severe ulcerative colitis, toxic megacolon, tachycardia.
  • Caution: Cardiac disease, HTN, hyperthyroidism, BPH, hiatal hernia with reflux, pregnancy/lactation (Category B2/C).
  • Drug Interactions: Additive anticholinergic effects with TCAs, antihistamines, antipsychotics, atropine, other antispasmodics. ↓ absorption of ketoconazole, digoxin. ↑ tachycardia risk with beta-agonists.
  • Vitals: Baseline HR, BP (anticholinergics ↑ HR).
  • Pain assessment: Location, severity, character—confirm spasmodic etiology.

Administration

  • Route: Oral (tablet 10 mg), IM, IV (ampoule 20 mg/mL).
  • Adult Dose: 10–20 mg TID–QID oral; 20 mg IM/IV q4–6h PRN (max 100 mg/day).
  • IV Technique: Slow push over 1–2 min (or dilute in 50 mL NS over 15–30 min) to minimize local irritation/tachycardia.
  • Pediatric: 6–12 yrs: 10 mg TID; <6 yrs: not recommended (safety not established).

Monitoring

  • Therapeutic: Pain relief (spasm reduction), bowel/bladder function.
  • Adverse Effects:
    • Common: Dry mouth, blurred vision, urinary retention, constipation, tachycardia, dizziness, N/V.
    • Serious: Angle-closure glaucoma precipitation, severe urinary retention, paralytic ileus, anaphylaxis.
  • IV Site: Check q1–2h for phlebitis/infiltration; rotate site q48–72h.

Patient Education

  • Purpose, dose, schedule, duration.
  • Side effects: dry mouth (sips water, sugar-free gum), blurred vision (avoid driving), urinary hesitancy (report inability to void).
  • Avoid alcohol (additive sedation).
  • Complete course even if symptoms improve.
  • Report: eye pain, vision changes, unable to urinate, severe constipation, palpitations.

Storage

Room temperature (15–30°C), dry, protected from light. Keep away from children.

Always verify orders against facility protocols and current drug references.

Nursing Homes - Related Articles